Treace Medical Concepts, Inc. ( (TMCI) ) has released its Q4 earnings. Here is a breakdown of the information Treace Medical Concepts, Inc. presented to its investors.
Treace Medical Concepts, Inc. is a medical technology company specializing in the surgical treatment of bunions and related midfoot deformities, utilizing innovative procedures such as Lapiplasty® and Adductoplasty®. The company is at the forefront of advancing surgical care in this niche market.
In its latest earnings report, Treace Medical Concepts announced a 10% increase in revenue for the fourth quarter of 2024, reaching $68.7 million, and a 12% increase for the full year, totaling $209.4 million. The company also reported a significant improvement in its adjusted EBITDA, which increased by 322% in the fourth quarter compared to the same period in 2023.
Key financial highlights include a reduction in net loss to $0.5 million for the fourth quarter, down from $6.3 million in the previous year, and a robust pipeline of research and development that promises to expand their technology offerings. The company also expanded its global patent portfolio and increased its active surgeon base by 10% over the year.
Looking ahead, Treace Medical Concepts is optimistic about its growth prospects, projecting a revenue increase of 7% to 10% for 2025. The company aims to continue its strategic investments and innovations to further penetrate the bunion market and improve its financial performance.